Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.

Date publication

avril 2020

Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Pr COUTANT Charles , Dr BENGRINE-LEFEVRE Leila , Pr AKLADIOS Chérif

Tous les auteurs :
Vincent L, Jankowski C, Ouldamer L, Ballester M, Bendifallah S, Bolze PA, Akladios C, Costaz H, Lavoué V, Canlorbe G, Collinet P, Touboul C, Huchon C, Bricou A, Dridi S, Padéano MM, Bengrine L, Arnould L, Coutant C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32417154

Résumé

The aim of this study was to identify prognostic factors of overall survival in patients with FIGO stage IIIc or IVa ovarian cancer (OC) treated by neo-adjuvant chemotherapy (NAC) followed by interval debulking surgery.

Mots clés

Interval debulking surgery, Neoadjuvant chemotherapy, Ovarian cancer, Overall survival

Référence

Eur J Surg Oncol. 2020 Apr 24;: